A random mutagenesis technique was used to predict the evolutionary potential of -lactamase CTX-M-9 toward the acquisition of improved catalytic activity against ceftazidime. Thirty CTX-M mutants were obtained during three rounds of mutagenesis. These mutants conferred 1-to 128-fold-higher MICs of ceftazidime than the parental enzyme CTX-M-9. The CTX-M mutants contained one to six amino acid substitutions. Mutants harbored the substitutions Asp240Gly and Pro167Ser, which were previously observed in clinical CTX-M enzymes. Additional substitutions, notably Arg164His, Asp179Gly, and Arg276Ser, were observed near the active site. The kinetic constants of the three most active mutants revealed two distinct ways of improving catalytic efficiency against ceftazidime. One enzyme had a 17-fold-higher k cat value than CTX-M-9 against ceftazidime. The other two had 75-to 300-fold-lower K m values than CTX-M-9 against ceftazidime. The current emergence of CTX-M -lactamases with improved activity against ceftazidime may therefore be the beginning of an evolutionary process which might subsequently generate a great diversity of CTX-M-type ceftazidimases.The most prevalent mechanism of resistance against -lactams in gram-negative bacilli is the production of -lactamases belonging to structural class A (1). Class A -lactamases are active-site serine enzymes which cleave the amide bond in the -lactam ring via an acyl-enzyme intermediate.Oxyimino cephalosporins, such as ceftazidime or cefotaxime, are highly resistant to this hydrolysis by class A penicillinases such as TEM-1, TEM-2, and SHV-1. However, the extensive use of these -lactams has resulted in the emergence of extended-spectrum -lactamases (ESBLs). The first ESBLs were derived from the TEM-1/2 and SHV-1 -lactamases by critical amino acid substitutions which confer hydrolytic activity against oxyimino cephalosporins. The major substitutions are located in two elements of the binding site: the 3 strand at position 238 and the omega loop at positions 164 and 179 (27).Non-TEM, non-SHV ESBLs designated CTX-M enzymes were identified in the early 1990s (2, 36). The frequency of CTX-M enzymes has increased sharply worldwide since 1995, and they now form a growing family that comprises more than 40 enzymes (3). Most CTX-M enzymes exhibit a much greater hydrolytic efficiency against cefotaxime than against ceftazidime, unlike TEM-and SHV-type ESBLs. However, seven CTX-M mutants harboring point mutations which improve enzymatic efficiency against ceftazidime have been reported recently, suggesting that CTX-Ms are altering their substrate specificity in response to continued antibiotic selective pressure. Five mutants harbor substitution Asp240Gly (4,5,16,29,31), and two mutants harbor substitutions Pro167Ser/Thr (33, 38). These substitutions have not been previously observed in natural TEM or SHV ESBLs, suggesting that CTX-M enzymes have a singular evolutionary potential. In this work, a random mutagenesis technique was applied to the CTX-M-9-encoding gene to predict wh...